{
    "clinical_study": {
        "@rank": "152886", 
        "arm_group": [
            {
                "arm_group_label": "Group A: SeV-G(NP) followed by Ad35-GRIN", 
                "arm_group_type": "Experimental", 
                "description": "SeV-G(NP) (IN) at 2x10^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)"
            }, 
            {
                "arm_group_label": "Group B: SeV-G(NP) followed by Ad35-GRIN", 
                "arm_group_type": "Experimental", 
                "description": "SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)"
            }, 
            {
                "arm_group_label": "Group C: Ad35-GRIN followed by SeV-G(NP)", 
                "arm_group_type": "Experimental", 
                "description": "Ad35-GRIN (IM) at 1x10^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10^8 CIU at Month 4. (Vaccine/Placebo = 12/4)"
            }, 
            {
                "arm_group_label": "Group D: SeV-G(NP) only", 
                "arm_group_type": "Experimental", 
                "description": "SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 and 4. (Vaccine/Placebo = 12/4)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability and immunogenicity of\n      Sendai HIV vaccine SeV-G(NP) given intranasally and Ad35-GRIN administered intramuscularly\n      in prime-boost regimens in HIV-uninfected, healthy adult volunteers."
        }, 
        "brief_title": "Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is a randomized, double-blind, placebo-controlled, dose-escalation trial assessing\n      the safety, tolerability, and immunogenicity of SeV-G(NP) given intranasally by drops and\n      Ad35-GRIN administered intramuscularly in each of four prime-boost regimens.\n\n      Volunteers will be screened up to 42 days before the 1st vaccination and will be followed\n      for 12 months after the last vaccine administration (16 months after the first vaccination).\n      It is anticipated that it will take approximately 6 months to enroll the study.\n      Approximately 64 volunteers (48 vaccine and 16 placebo recipients) will be included in the\n      study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy male or female adults,\n\n          -  18 to 50 years of age (21 to 50 years of age for volunteers in Rwanda),\n\n          -  who do not report high-risk behaviour for HIV infection,\n\n          -  who are available for the duration of the trial,\n\n          -  who are willing to undergo HIV testing,\n\n          -  use an effective method of contraception, and\n\n          -  who, in the opinion of the principal investigator or designee, understand the study\n             and who provide written informed consent.\n\n        Exclusion Criteria:\n\n          -  confirmed HIV infection,\n\n          -  pregnancy and lactation,\n\n          -  significant acute or chronic disease,\n\n          -  clinically significant laboratory abnormalities,\n\n          -  recent vaccination or receipt of a blood product,\n\n          -  previous receipt of an HIV vaccine, and\n\n          -  previous severe local or systemic reactions to vaccination or history of severe\n             allergic reactions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01705990", 
            "org_study_id": "IAVI S001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A: SeV-G(NP) followed by Ad35-GRIN", 
                "description": "Delivered intranasally by drops", 
                "intervention_name": "SeV-G(NP) (0.2mL, 2x10^7 CIU)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group B: SeV-G(NP) followed by Ad35-GRIN", 
                    "Group C: Ad35-GRIN followed by SeV-G(NP)", 
                    "Group D: SeV-G(NP) only"
                ], 
                "description": "Delivered intranasally by drops", 
                "intervention_name": "SeV-G(NP) (0.2mL, 2x10^8 CIU)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group A: SeV-G(NP) followed by Ad35-GRIN", 
                    "Group B: SeV-G(NP) followed by Ad35-GRIN", 
                    "Group C: Ad35-GRIN followed by SeV-G(NP)"
                ], 
                "description": "(1x10^10 vp) Delivered intramuscularly by standard syringe and needle injection", 
                "intervention_name": "Ad35-GRIN (0.5mL)", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV", 
            "AIDS", 
            "HIV vaccine", 
            "HIV prevention"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "link": {
            "description": "International AIDS Vaccine Initiative", 
            "url": "http://www.iavi.org"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nairobi", 
                        "country": "Kenya"
                    }, 
                    "name": "Kenya AIDS Vaccine Initiative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kigali", 
                        "country": "Rwanda"
                    }, 
                    "name": "Project San Francisco"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "St. Stephen's Centre"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Kenya", 
                "Rwanda", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase I Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of a Sendai HIV Vaccine SeV-G(NP) Given Intranasally and Ad35-GRIN Administered Intramuscularly in Prime-Boost Regimens in HIV-Uninfected, Healthy Adult Volunteers", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Rwanda: Ethics Committee", 
                "Rwanda: Ministry of Health", 
                "Kenya: Kenyatta National Hospital/University of Nairobi Ethics and Research Committee", 
                "Kenya: Ministry of Health", 
                "Kenya: Pharmacy and Poisons Board", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety and tolerability of SeV-G(NP) and Ad35-GRIN administered in four prime-boost regimens.", 
            "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "16 months approximately"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01705990"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess the presence and persistence of the SeV-G(NP) vector and the in vivo genetic integrity of the insert", 
                "measure": "Shedding", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }, 
            {
                "description": "To assess (qualitative and quantitative) immune responses elicited by the different prime-boost regimens.", 
                "measure": "Immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }
        ], 
        "source": "International AIDS Vaccine Initiative", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "International AIDS Vaccine Initiative", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}